-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
Guangxiang Pharmaceutical, part of Shijiazhuang Four Pharmaceutical Group: Delivers an “innovative combination punch” to seize the initiative in development.
Category:
Time:2022-04-20
【概要描述】
Our flagship product, caffeine, and other related products have all seen robust growth in both production and sales. Seven new specialty pharmaceutical ingredients—including hexamethylenetetramine and ornidazole—are set to receive approval and launch soon. In the first quarter, our core business revenue achieved triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has delivered an impressive “combination punch,” ushering in a strong start to its innovative development.
Its flagship product—caffeine—has seen robust growth across the board in both production and sales. Seven new specialty pharmaceutical ingredients, including pentoxifylline and ornidazole, are poised to receive approval and enter the market soon. In the first quarter, the company’s core business revenue achieved triple-digit growth... Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has delivered a stunning “combination punch,” ushering in a strong start to its innovative development.
“By seizing opportunities and extending and strengthening our industrial chain, this strategic move has created new growth prospects for us. The strong performance in the first quarter was, to a certain extent, driven by our successful mergers and acquisitions. In early March, we acquired 100% equity of Cangzhou Lingang Youyi Chemical Co., Ltd.—a leading domestic producer of methylamine compounds—giving Guangxiang Pharmaceutical an even greater boost and adding significant weight to our ability to compete in the market.” Speaking enthusiastically about this successful capital operation, Cui Yongbin, Chairman of Guangxiang Pharmaceutical, explained that caffeine is highly sought after in the international market, and maintaining tight control over production costs is the key to continuously winning market share. Among the various components of caffeine production costs, monomethylamine accounts for a substantial portion. By acquiring Youyi Chemical, which operates within the same industrial park, Guangxiang Pharmaceutical has not only reaped tangible benefits in terms of reducing caffeine production costs but has also effectively addressed issues related to upstream-downstream integration and supply-chain management. As a result, the company’s industrial chain has become more complete and streamlined, giving it greater influence and bargaining power in both domestic and international markets.
“Capital mergers and acquisitions are commendable, but technological advancements have also played an equally crucial role. This strategic move has firmly strengthened our core competitiveness,” said Cui Yongbin. Guangxiang Pharmaceutical serves as the origin for Shisi Pharmaceutical Group’s efforts to build an integrated “API + finished dosage form” business model, accelerate industrial transformation, and implement measures to complete, extend, and strengthen the supply chain. The company aims to establish itself as a new high ground for innovative, high-quality development of APIs in China, making it a cornerstone of the industry’s growth. In recent years, leveraging research-and-development approaches such as the “listing-and-command” system, Guangxiang Pharmaceutical has driven collaborative攻关 on key core technologies essential for API production. Through flexible talent recruitment and with guidance from research teams at Tsinghua University and Tianjin University, Guangxiang Pharmaceutical has successfully addressed several common and critical technical challenges that previously hindered the yield and quality of its flagship product—caffeine—resulting in a doubling of production capacity and achieving full-scale output. In the first quarter, the plant’s caffeine exports accounted for more than 30% of the country’s total caffeine exports. Meanwhile, the efficiency of new-product R&D is also accelerating. Seven new products—including pentoxifylline, ornidazole, levornidazole, and pitavastatin calcium—are set to receive approval and enter the market soon, further highlighting the exemplary role of “specialized, refined, distinctive, and innovative” enterprises and “little giants” in driving industrial development.
Stepping into the production workshop of Guangxiang Pharmaceutical, one is immediately struck by the presence of advanced, modern, and intelligent equipment everywhere. “Promoting and applying cutting-edge production equipment demonstrates our forward-looking vision and confidence in aligning with global industry trends. Since the beginning of this year, we’ve been actively rolling out digital information management systems, striving to build an intelligent API factory that meets internationally advanced standards. Now, by adopting new, intelligent crystal-form control technology, we can effortlessly regulate product particle size and bulk density, meeting the diverse needs of high-end customers in Europe and the U.S. This has significantly improved flowability indicators for products such as caffeine and metronidazole, earning our products widespread trust among customers.” Cui Yongbin spoke with great enthusiasm, adding that by introducing and deeply integrating internationally advanced smart manufacturing equipment and core industrial software, they’ve achieved “one-click” control over the entire production process for a range of products—including caffeine, theophylline, aminophylline, metronidazole, and nifedipine—elevating their smart manufacturing scale and level to a domestic leading position. Currently, Guangxiang Pharmaceutical has successively obtained national GMP certification as well as international certifications such as BRC, FSSC22000, KOSHER, and HALAL, and has established strong cooperative relationships with major global caffeine buyers.
“Next, we will seize the policy opportunities presented by the nation’s efforts to build a unified national market, continue to ramp up our investment in innovation, and accelerate the implementation of new-product industrialization projects. By delivering high-quality supply that creates and leads demand, we will proactively explore forward-looking and driving market opportunities, and steadily strengthen and enhance our appeal to both domestic and international markets,” said Cui Yongbin with great confidence.
Keywords:
Recommended
Share to
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license